ShapeTX is devloping programmable RNA medicines to repair the genetic causes of disease. It achieves this by merging innovations in AI and RNA technology to generate and analyze hundreds of billions of therapeutic possibilities which enables breakthroughs in RNA editing, next-generation AAVs, and gene therapy manufacturing.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze